Belite Bio (BLTE) Short-term Investments (2024 - 2025)
Belite Bio (BLTE) recorded quarterly Short-term Investments of $139.5 million in Q4 2025, up 28.06% quarter-over-quarter from $108.9 million in Q4 2024, and up 28.06% on a YoY basis from $108.9 million in Q4 2024.
Belite Bio (BLTE) Short-term Investments (2024 - 2025) Analysis & Trends
Belite Bio's Short-term Investments history runs 2 years deep, the most recent figure standing at $139.5 million for Q4 2025.
- In Q4 2025, Short-term Investments rose 28.06% year-over-year to $139.5 million; the TTM figure through Dec 2025 stood at $139.5 million (up 28.06% YoY), while the FY2025 annual figure was $139.5 million, up 28.06% from the prior year.
- Short-term Investments was $139.5 million for Q4 2025 at Belite Bio, up from $108.9 million in the prior quarter.
- In the past five years, Short-term Investments ranged from a high of $139.5 million in Q4 2025 to a low of $108.9 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Regeneron Pharmaceuticals | 63.43 Bn | 54.67 Bn | 3.31 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 139.49 Mn |
| Dec 31, 2024 | 108.92 Mn |